Current research on chronic active Epstein–Barr virus infection in Japan
暂无分享,去创建一个
T. Morio | E. Kodama | H. Kimura | H. Wakiguchi | A. Arai | N. Shimizu | S. Fujiwara | K. Imadome
[1] S. Kojima,et al. Plasma viral microRNA profiles reveal potential biomarkers for chronic active Epstein-Barr virus infection. , 2013, The Journal of infectious diseases.
[2] H. Kanegane,et al. SAP and XIAP deficiency in hemophagocytic lymphohistiocytosis , 2012, Pediatrics international : official journal of the Japan Pediatric Society.
[3] T. Miyake,et al. Hydroa vacciniforme is associated with increased numbers of Epstein-Barr virus-infected γδT cells. , 2012, The Journal of investigative dermatology.
[4] Takashi Saito,et al. Antitumor activities of valproic acid on Epstein–Barr virus‐associated T and natural killer lymphoma cells , 2012, Cancer science.
[5] T. Naoe,et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. , 2012, Blood.
[6] K. Sugimoto,et al. T/NK cell type chronic active Epstein–Barr virus disease in adults: an underlying condition for Epstein–Barr virus-associated T/NK-cell lymphoma , 2012, Journal of Clinical Pathology.
[7] K. Sugimoto,et al. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein‐Barr virus infection , 2011, International journal of cancer.
[8] K. Kawa,et al. Clinicopathological analysis of the age‐related differences in patients with Epstein–Barr virus (EBV)‐associated extranasal natural killer (NK)/T‐cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection‐associated lymphoproliferative disorde , 2011, Histopathology.
[9] T. Morio,et al. Novel Mouse Xenograft Models Reveal a Critical Role of CD4+ T Cells in the Proliferation of EBV-Infected T and NK Cells , 2011, PLoS pathogens.
[10] W. Wilson,et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. , 2011, Blood.
[11] C. Nakaseko,et al. Clinical features of adult-onset chronic active Epstein–Barr virus infection: a retrospective analysis , 2011, International journal of hematology.
[12] S. Ichiyama,et al. Multicenter evaluation of prototype real‐time PCR assays for Epstein‐Barr virus and cytomegalovirus DNA in whole blood samples from transplant recipients , 2010, Microbiology and immunology.
[13] Y. Yamauchi,et al. Identification of Epstein-Barr virus (EBV)-infected lymphocyte subtypes by flow cytometric in situ hybridization in EBV-associated lymphoproliferative diseases. , 2009, The Journal of infectious diseases.
[14] D. Bartel. MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.
[15] K. Kawa,et al. Allogeneic hematopoietic stem cell transplantation for Epstein–Barr virus‐associated T/natural killer‐cell lymphoproliferative disease in Japan , 2008, American journal of hematology.
[16] K. Ohshima,et al. Proposed categorization of pathological states of EBV‐associated T/natural killer‐cell lymphoproliferative disorder (LPD) in children and young adults: Overlap with chronic active EBV infection and infantile fulminant EBV T‐LPD , 2008, Pathology international.
[17] J. Cohen,et al. Bortezomib Induces Apoptosis of Epstein-Barr Virus (EBV)-Transformed B Cells and Prolongs Survival of Mice Inoculated with EBV-Transformed B Cells , 2007, Journal of Virology.
[18] A. Rickinson,et al. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. , 2007, Annual review of immunology.
[19] M. Pomper,et al. Virus-Associated Tumor Imaging by Induction of Viral Gene Expression , 2007, Clinical Cancer Research.
[20] M. Aricò,et al. HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis , 2007, Pediatric blood & cancer.
[21] S. Kenney,et al. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. , 2006, Cancer research.
[22] H. Kimura. Pathogenesis of chronic active Epstein‐Barr virus infection: Is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? , 2006, Reviews in medical virology.
[23] Alexandra Schäfer,et al. Epstein–Barr Virus MicroRNAs Are Evolutionarily Conserved and Differentially Expressed , 2006, PLoS pathogens.
[24] S. Nonoyama,et al. Coexpression of CD40 and CD40 ligand in Epstein-Barr virus-infected T and NK cells and their role in cell survival. , 2005, The Journal of infectious diseases.
[25] H. Kanegane,et al. Proposed guidelines for diagnosing chronic active Epstein‐Barr virus infection , 2005, American journal of hematology.
[26] Longxing Wei,et al. Distribution and phenotype of Epstein–Barr virus-infected cells in human pharyngeal tonsils , 2005, Modern Pathology.
[27] S. Kojima,et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. , 2005, The Journal of infectious diseases.
[28] T. Tsurumi,et al. Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T cells in patients with chronic active EBV infection. , 2004, The Journal of infectious diseases.
[29] T. Oono,et al. A spectrum of clinical manifestations caused by host immune responses against Epstein-Barr virus infections. , 2004, Acta medica Okayama.
[30] Anton J. Enright,et al. Identification of Virus-Encoded MicroRNAs , 2004, Science.
[31] E. Jaffe,et al. Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. , 2004, Blood.
[32] T. Morio,et al. Characterization of Epstein‐Barr Virus (EBV)‐Positive NK Cells Isolated from Hydroa Vacciniforme‐Like Eruptions , 2003, Microbiology and immunology.
[33] P. Brousset,et al. Acquisition of Viral Receptor by NK Cells Through Immunological Synapse1 , 2003, The Journal of Immunology.
[34] H. Kanegane,et al. Prognostic factors for chronic active Epstein-Barr virus infection. , 2003, The Journal of infectious diseases.
[35] M. Okano. Overview and problematic standpoints of severe chronic active Epstein-Barr virus infection syndrome. , 2002, Critical reviews in oncology/hematology.
[36] J. Adams. Proteasome inhibition: a novel approach to cancer therapy. , 2002, Trends in molecular medicine.
[37] T. Okamura,et al. Mosquito allergy and Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease. , 2001, Blood.
[38] H. Ishiko,et al. Heterogeneous, restricted patterns of Epstein-Barr virus (EBV) latent gene expression in patients with chronic active EBV infection. , 2001, The Journal of general virology.
[39] Y. Sakiyama,et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. , 2001, Blood.
[40] H. Kanegane,et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. , 2001, Blood.
[41] H. Matsuoka,et al. Impaired cytotoxic T lymphocyte response to Epstein‐Barr virus‐infected NK cells in patients with severe chronic active EBV infection , 2001, Journal of medical virology.
[42] H. Takada,et al. Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. , 2000, The Journal of infectious diseases.
[43] T. Okamura,et al. Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. , 2000, The Lancet.
[44] James F. Jones,et al. Elevated Serum Transforming Growth Factor β1 Levels in Epstein-Barr Virus-Associated Diseases and Their Correlation with Virus-Specific Immunoglobulin A (IgA) and IgM , 2000, Journal of Virology.
[45] Akiba,et al. The association of latent Epstein–Barr virus infection with hydroa vacciniforme , 1999, The British journal of dermatology.
[46] K. Iwatsuki,et al. Atypical hydroa vacciniforme in childhood: from a smoldering stage to Epstein-Barr virus-associated lymphoid malignancy. , 1999, Journal of the American Academy of Dermatology.
[47] J. Chen,et al. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. , 1997, The Journal of clinical investigation.
[48] K. Hirai,et al. Clonal lymphoproliferation following chronic active Epstein‐Barr virus infection and hypersensitivity to mosquito bites , 1997, American journal of hematology.
[49] K. Ohshima,et al. Hypersensitivity to Mosquito Bites Conceals Clonal Lymphoproliferation of Epstein‐Barr Viral DNA‐positive Natural Killer Cells , 1997, Japanese journal of cancer research : Gann.
[50] H. Tsutsumi,et al. Epstein-Barr virus (EBV)-carrying and -expressing T-cell lines established from severe chronic active EBV infection. , 1996, Blood.
[51] H. Stein,et al. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. , 1995, Blood.
[52] Y. Sakiyama,et al. Fatal Epstein-Barr virus-associated hemophagocytic syndrome. , 1993, Blood.
[53] M. Fujieda,et al. Defective activity of Epstein‐Barr virus (EBV) specific cytotoxic T lymphocytes in children with chronic active EBV infection and in their parents , 1993, Acta paediatrica Japonica : Overseas edition.
[54] H. Kawaguchi,et al. Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome. , 1993, The Journal of clinical investigation.
[55] U. Nater,et al. Epstein-Barr virus. , 1991, The Journal of family practice.
[56] K. Hirai,et al. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. , 1989, The Journal of clinical investigation.
[57] K. Hirai,et al. Clonal T‐cell Lymphoproliferation Containing Epstein‐Barr (EB) Virus DNA in a Patient with Chronic Active EB Virus Infection , 1989, Japanese journal of cancer research : Gann.
[58] I. Kobayashi,et al. Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease , 1988, Nature.
[59] James F. Jones,et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. , 1988, The New England journal of medicine.
[60] D. Purtilo,et al. Chronic Mononucleosis Syndrome , 1984, Southern medical journal.
[61] M. Goldgeier,et al. Hydroa vacciniforme: diagnosis and therapy. , 1982, Archives of dermatology.
[62] M. Epstein,et al. VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. , 1964, Lancet.
[63] 河邉 慎司. Application of flow cytometric in situ hybridization assay to Epstein-Barr virus-associated T/natural killer cell lymphoproliferative diseases , 2013 .
[64] Y. Ota,et al. Recurrence of chronic active Epstein-Barr virus infection from donor cells after achieving complete response through allogeneic bone marrow transplantation. , 2012, Internal medicine.
[65] T. Okamura,et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection , 2011, Bone Marrow Transplantation.
[66] Ayako AraiKen-Ichi. Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis , 2011 .
[67] E. Jaffe,et al. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. , 2009, Hematology. American Society of Hematology. Education Program.
[68] A. Rickinson. Chronic, symptomatic Epstein-Barr virus infections. , 1986, Immunology today.